A Randomized Controlled Study of Rolapitant for the Prevention of Nausea and Vomiting Following Surgery (Study P04937AM1)(COMPLETED) - Full Text View

Sponsor:	Schering-Plough
Information provided by:	Schering-Plough
ClinicalTrials.gov Identifier:	NCT00539721

Purpose

This is a multicenter, randomized, controlled study in women who are having elective open abdominal surgery with general anesthesia and who are expected to need patient-controlled analgesia (PCA) after surgery. The primary objective is to assess the effect of rolapitant in the prevention of postoperative nausea and vomiting as measured by the prevention of vomiting in the first 24 hours after surgery. Participation in the study may last up to 3 months. The total duration of the study will be approximately 36 weeks.

Condition	Intervention	Phase
Postoperative Nausea and Vomiting	Drug: Rolapitant Dose 1 Drug: Rolapitant Dose 2 Drug: Rolapitant Dose 3 Drug: Rolapitant Dose 4 Drug: Ondansetron Drug: Placebo	Phase II

Study Type:	Interventional
Study Design:	Prevention, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	A Randomized, Double-Blind, Double-Dummy, Dose-Ranging, Active- and Placebo-Controlled Study of Single-Dose Oral Rolapitant Monotherapy for the Prevention of Postoperative Nausea and Vomiting (PONV)

Resource links provided by NLM:

MedlinePlus related topics: Nausea and Vomiting Surgery

Drug Information available for: Ondansetron hydrochloride Ondansetron

U.S. FDA Resources

Further study details as provided by Schering-Plough:

Primary Outcome Measures:

No emetic episodes regardless of rescue medication use. [ Time Frame: First 24 hours after surgery. ] [ Designated as safety issue: No ]

Estimated Enrollment:	600
Study Start Date:	October 2007
Study Completion Date:	July 2008
Primary Completion Date:	July 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Rolapitant Dose 1: Experimental	Drug: Rolapitant Dose 1 Rolapitant 5 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
Rolapitant Dose 2: Experimental	Drug: Rolapitant Dose 2 Rolapitant 20 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
Rolapitant Dose 3: Experimental	Drug: Rolapitant Dose 3 Rolapitant 70 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
Rolapitant Dose 4: Experimental	Drug: Rolapitant Dose 4 200 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
Ondansetron: Active Comparator	Drug: Ondansetron Ondansetron 4 mg x 1 intravenous and rolapitant placebo (4 capsules) x 1 oral on Day 1
Placebo: Placebo Comparator	Drug: Placebo Rolapitant placebo (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Women aged 18 years or older of any race with an American Society of Anesthesiologists (ASA) physical status of I to III who are scheduled to undergo elective open abdominal surgery under general anesthesia.
Women whose postoperative hospitalization is expected to last at least 24 hours
Women expected to require postoperative intravenous opioid PCA.
Women whose surgery is expected to require at least 1 hour, but not more than 4 hours, of general anesthesia using the regimen defined in this protocol.
Women of childbearing potential who have a negative pregnancy test or women who have been surgically sterilized or are postmenopausal.

Exclusion Criteria:

Women with clinically significant or unstable cardiac, respiratory, hepatic, renal, or other major organ system disease.
Women with a known hypersensitivity to ondansetron (or any other 5-HT3 antagonist), to any agent that is part of the anesthesia regimen, or to other medications to be administered under this protocol.
Women who are scheduled to undergo certain types of surgery.
Women who are breastfeeding.
Women who have retching/vomiting or moderate or severe nausea in the 24 hours prior to surgery or suffer from chronic nausea and/or vomiting.
Women with a body mass index (BMI) >40.
Women who have participated in a clinical trial of an investigational drug within 30 days prior to drug administration.

Contacts and Locations

No Contacts or Locations Provided

More Information

No publications provided

Responsible Party:	Schering-Plough ( Head, Clinical Trials Registry & Results Disclosure Group )
Study ID Numbers:	P04937
Study First Received:	October 2, 2007
Last Updated:	October 16, 2009
ClinicalTrials.gov Identifier:	NCT00539721 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Schering-Plough:

Nausea
Vomiting

Additional relevant MeSH terms:

Neurotransmitter Agents
Vomiting
Signs and Symptoms, Digestive
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Psychotropic Drugs
Antiemetics
Signs and Symptoms
Serotonin Antagonists
Pathologic Processes
Therapeutic Uses
Antipruritics
Nausea
Ondansetron

Dermatologic Agents
Postoperative Nausea and Vomiting
Tranquilizing Agents
Gastrointestinal Agents
Central Nervous System Depressants
Antipsychotic Agents
Pharmacologic Actions
Serotonin Agents
Postoperative Complications
Autonomic Agents
Anti-Anxiety Agents
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on November 30, 2009